This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
General Electric (GE) Q1 Earnings Lag Estimates, View Gloomy
by Zacks Equity Research
General Electric's (GE) first-quarter 2020 earnings reflect the adverse impacts of the coronavirus outbreak. Persistence of the headwinds is likely to impact second-quarter results as well.
The Coronavirus Impact on Corporate Earnings
by Sheraz Mian
We discuss today the Covid-19 impact on corporate earnings, in addition to featuring new research reports on AP (SAP), NIKE (NKE) and others.
Healthy Business to Aid Danaher in Q1 Despite Coronavirus Woes
by Zacks Equity Research
Danaher's (DHR) healthy businesses are likely to aid, driven by segmental performances in the first quarter of 2020. However, concerns related to the coronavirus outbreak persist.
When Does Market Timing Actually Work? - April 14, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
General Electric Take Multiple Debt Restructuring Actions
by Zacks Equity Research
General Electric (GE) commences multiple actions to strengthen its financial positions. Proceeds from the BioPharma divestment and new debt offerings have been used for reducing leverage.
Danaher Gives Update on Q1 Results, Withdraws 2020 Guidance
by Zacks Equity Research
Danaher (DHR) provides an update on first-quarter 2020 results and withdraws its earlier announced guidance for 2020 on the impacts of the coronavirus outbreak.
General Electric Withdraws 2020 View on Coronavirus Concerns
by Zacks Equity Research
General Electric (GE) suspends 2020 projections on uncertainties related to the coronavirus outbreak. Also, earnings in the first quarter are expected to be weaker than previously expected.
Analysts Estimate Danaher (DHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher (DHR) Prices Senior Notes Offering Worth Euro 750M
by Zacks Equity Research
Danaher (DHR) prices euro 750 million worth of senior notes offerings. The net proceeds will be used for satisfying generate corporate purposes, including repaying debts.
Danaher Closes Buyout of General Electric's BioPharma Business
by Zacks Equity Research
Danaher (DHR) completes the acquisition of General Electric's BioPharma business. The buyout will likely strengthen the company's biologics workflow solutions business.
General Electric Closes Divestment of BioPharma to Danaher
by Zacks Equity Research
General Electric (GE) completes the divestment of its BioPharma business to Danaher. The net proceeds received from the transaction will be used by General Electric to lower its debt burden.
Top Stock Reports for Stryker, Shopify & Activision Blizzard
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Stryker (SYK), Shopify (SHOP) and Activision Blizzard (ATVI).
Danaher (DHR) Prices Euro 1.75B Worth Senior Notes Offering
by Zacks Equity Research
Danaher (DHR) prices euro 1.75 billion worth of senior notes offerings. The net proceeds will be used for satisfying generate corporate purposes, including repaying debts.
Conglomerates Accelerate Efforts to Fight Coronavirus Menace
by Avisekh Bhattacharjee
Several industrial conglomerates including General Electric (GE), Honeywell (HON), Danaher (DHR) and 3M (MMM) are increasing steps to mitigate the effects of the coronavirus menace.
General Electric Announces Coronavirus' Impacts on Its Business
by Zacks Equity Research
General Electric's (GE) aviation segment seeks to lower the U.S. workforce by 10% on coronavirus concerns. The company announces various other measures to deal with the impact of the outbreak.
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
Top Stock Reports for Visa, Bank of America & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Bank of America (BAC) and Citigroup (C).
Coronavirus Test Kit Demand to Drive These 3 Stocks
by Zacks Equity Research
Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.
Danaher to Soon Close BioPharma Buyout, Receives FTC Approval
by Zacks Equity Research
Danaher (DHR) receives a go-ahead for the acquisition of GE's BioPharma business. The buyout will likely strengthen its biologics workflow solutions business.
Yes, You Can Time the Market. Find out How - March 20, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Align Technology to Acquire exocad in Digital Dentistry Space
by Zacks Equity Research
This acquisition is expected to boost Align Technology's (ALGN) portfolio of Invisalign and iTero digital solutions.
Danaher (DHR) Poised to Gain From Buyouts Despite Cost Woes
by Zacks Equity Research
Danaher (DHR) to gain from synergistic benefits from acquired assets as well as innovation efforts and shareholder-friendly policies. High costs and debts along with forex woes might be dragging.
The Truth About Market Timing - March 02, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Why Is Danaher (DHR) Down 14.5% Since Last Earnings Report?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Truth About Market Timing - February 07, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?